Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019

Clin Infect Dis. 2021 Nov 2;73(9):e3110-e3112. doi: 10.1093/cid/ciaa1463.


The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.

Keywords: HLH; COVID-19; HScore; cytokine storm.

MeSH terms

  • COVID-19*
  • Humans
  • Lymphohistiocytosis, Hemophagocytic* / diagnosis
  • Risk Factors
  • SARS-CoV-2